{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:00:39Z","timestamp":1784394039826,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS Grant-in-Aid for Early-Career Scientists","award":["P22K15326"],"award-info":[{"award-number":["P22K15326"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00280-023-04584-x","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:02:08Z","timestamp":1693504928000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer"],"prefix":"10.1007","volume":"92","author":[{"given":"Yukitaka","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-6690","authenticated-orcid":false,"given":"Ken-ichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"4584_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","volume":"40","author":"B Reigner","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85\u2013104. https:\/\/doi.org\/10.2165\/00003088-200140020-00002","journal-title":"Clin Pharmacokinet"},{"key":"4584_CR2","doi-asserted-by":"publisher","first-page":"175883591983896","DOI":"10.1177\/1758835919838964","volume":"11","author":"FM de Man","year":"2019","unstructured":"de Man FM, Veerman GDM, Oomen-de Hoop E, Deenen MJ, Meulendijks D, Mandigers C, Soesan M, Schellens JHM, van Meerten E, van Gelder T, Mathijssen RHJ (2019) Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine. Ther Adv Med Oncol 11:1758835919838964. https:\/\/doi.org\/10.1177\/1758835919838964","journal-title":"Ther Adv Med Oncol"},{"key":"4584_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40268-016-0154-8","volume":"17","author":"LW Leicher","year":"2017","unstructured":"Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JW (2017) Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. Drugs R D 17:117\u2013124. https:\/\/doi.org\/10.1007\/s40268-016-0154-8","journal-title":"Drugs R D"},{"key":"4584_CR4","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696\u20132704. https:\/\/doi.org\/10.1056\/NEJMoa043116","journal-title":"N Engl J Med"},{"key":"4584_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq069","author":"T Doi","year":"2010","unstructured":"Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Sato A, Koizumi W, Mizunuma N, Takiuchi H (2010) Phase I\/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyq069","journal-title":"Jpn J Clin Oncol"},{"key":"4584_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000354","author":"M Kotaka","year":"2018","unstructured":"Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M (2018) Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2018-000354","journal-title":"ESMO Open"},{"key":"4584_CR7","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.1998.16.5.1795","volume":"16","author":"DR Budman","year":"1998","unstructured":"Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T (1998) Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16:1795\u20131802. https:\/\/doi.org\/10.1200\/JCO.1998.16.5.1795","journal-title":"J Clin Oncol"},{"key":"4584_CR8","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","volume":"16","author":"M Mackean","year":"1998","unstructured":"Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer. J Clin Oncol 16:2977\u20132985. https:\/\/doi.org\/10.1200\/JCO.1998.16.9.2977","journal-title":"J Clin Oncol"},{"key":"4584_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00280-020-04087-z","volume":"85","author":"N Matsumoto","year":"2020","unstructured":"Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI (2020) Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol 85:1119\u20131128. https:\/\/doi.org\/10.1007\/s00280-020-04087-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"4584_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bcp.14441","volume":"87","author":"M Saez-Bello","year":"2021","unstructured":"Saez-Bello M, Mangas-Sanjuan V, Martinez-Gomez MA, Lopez-Montenegro Soria MA, Climente-Marti M, Merino-Sanjuan M (2021) Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. Br J Clin Pharmacol 87:905\u2013915. https:\/\/doi.org\/10.1111\/bcp.14441","journal-title":"Br J Clin Pharmacol"},{"key":"4584_CR11","unstructured":"The Human Protein Atlas https:\/\/www.proteinatlas.org\/. Accessed March 31, 2023"},{"key":"4584_CR12","unstructured":"dbSNP National Center for Biotechnology Information. https:\/\/www.ncbi.nlm.nih.gov\/snp\/. Accessed March 31, 2023"},{"key":"4584_CR13","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473\u20133478. https:\/\/doi.org\/10.1073\/pnas.97.7.3473","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4584_CR14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2217\/pgs.10.159","volume":"11","author":"E Gonzalez-Haba","year":"2010","unstructured":"Gonzalez-Haba E, Garcia MI, Cortejoso L, Lopez-Lillo C, Barrueco N, Garcia-Alfonso P, Alvarez S, Jimenez JL, Martin ML, Munoz-Fernandez MA, Sanjurjo M, Lopez-Fernandez LA (2010) ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 11:1715\u20131723. https:\/\/doi.org\/10.2217\/pgs.10.159","journal-title":"Pharmacogenomics"},{"key":"4584_CR15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3289","author":"X Garcia-Gonzalez","year":"2015","unstructured":"Garcia-Gonzalez X, Cortejoso L, Garcia MI, Garcia-Alfonso P, Robles L, Gravalos C, Gonzalez-Haba E, Marta P, Sanjurjo M, Lopez-Fernandez LA (2015) Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.3289","journal-title":"Oncotarget"},{"key":"4584_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00280-009-1029-2","volume":"65","author":"K Fujita","year":"2010","unstructured":"Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y (2010) Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 65:251\u2013258. https:\/\/doi.org\/10.1007\/s00280-009-1029-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"4584_CR17","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012. https:\/\/doi.org\/10.1200\/JCO.2007.14.9898","journal-title":"J Clin Oncol"},{"key":"4584_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177\u20131188. https:\/\/doi.org\/10.1056\/NEJMoa1713709","journal-title":"N Engl J Med"},{"key":"4584_CR19","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019. https:\/\/doi.org\/10.1200\/JCO.2007.14.9930","journal-title":"J Clin Oncol"},{"key":"4584_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","volume":"25","author":"HJ Schmoll","year":"2007","unstructured":"Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzen F, Haller DG (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102\u2013109. https:\/\/doi.org\/10.1200\/JCO.2006.08.1075","journal-title":"J Clin Oncol"},{"key":"4584_CR21","first-page":"3339","volume":"61","author":"B Vulevic","year":"2001","unstructured":"Vulevic B, Chen Z, Boyd JT, Davis W Jr, Walsh ES, Belinsky MG, Tew KD (2001) Cloning and characterization of human adenosine 5\u2019-triphosphate-binding cassette, sub-family a, transporter 2 (ABCA2). Cancer Res 61:3339\u20133347","journal-title":"Cancer Res"},{"key":"4584_CR22","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1158\/1078-0432.CCR-05-2587","volume":"12","author":"D Steinbach","year":"2006","unstructured":"Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T (2006) ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 12:4357\u20134363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2587","journal-title":"Clin Cancer Res"},{"key":"4584_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/path.1711760212","volume":"176","author":"SB Fox","year":"1995","unstructured":"Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL (1995) Platelet-derived endothelial cell growth factor\/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 176:183\u2013190. https:\/\/doi.org\/10.1002\/path.1711760212","journal-title":"J Pathol"},{"key":"4584_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","volume":"49","author":"C Poole","year":"2002","unstructured":"Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, Monkhouse J, Banken L, Weidekamm E, Reigner B (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:225\u2013234. https:\/\/doi.org\/10.1007\/s00280-001-0408-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4584_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/nu15040998","author":"M Matsuo","year":"2023","unstructured":"Matsuo M, Ogata Y, Yamanashi Y, Takada T (2023) ABCG5 and ABCG8 Are involved in vitamin K transport. Nutrients. https:\/\/doi.org\/10.3390\/nu15040998","journal-title":"Nutrients"},{"key":"4584_CR26","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1271\/bbb.70109","volume":"71","author":"S Tachibana","year":"2007","unstructured":"Tachibana S, Hirano M, Hirata T, Matsuo M, Ikeda I, Ueda K, Sato R (2007) Cholesterol and plant sterol efflux from cultured intestinal epithelial cells is mediated by ATP-binding cassette transporters. Biosci Biotechnol Biochem 71:1886\u20131895. https:\/\/doi.org\/10.1271\/bbb.70109","journal-title":"Biosci Biotechnol Biochem"},{"key":"4584_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"4584_CR28","unstructured":"CPIC Guideline for Fluoropyrimidine and DPYD. https:\/\/cpicpgx.org\/guidelines\/guideline-for-fluoropyrimidines-and-dpyd\/. Accessed August 15, 2023"},{"key":"4584_CR29","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1038\/s41598-017-07491-3","volume":"7","author":"Q Chen","year":"2017","unstructured":"Chen Q, Meng F, Wang L, Mao Y, Zhou H, Hua D, Zhang H, Wang W (2017) A polymorphism in ABCC4 is related to efficacy of 5-FU\/capecitabine-based chemotherapy in colorectal cancer patients. Sci Rep 7:7059. https:\/\/doi.org\/10.1038\/s41598-017-07491-3","journal-title":"Sci Rep"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04584-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T06:06:08Z","timestamp":1699596368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04584-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["4584"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04584-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Showa University. The study was registered with the University Hospital Medical Information Network-Clinical Trials Registry for Japan on July 26, 2017 (UMIN000031182).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave written informed consent for the use of their peripheral blood samples and medical information for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients gave written informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}